1. Risk of Transmission of Different Viruses Following Accidental Needle Injury Hepatitis B virus6-30% Hepatitis C virus0-7% (1.8%) Human Immunodeficiency Virus0.3%

3. Transmission of HIV Infection to HCPS Who is at risk? What is the risk? What are the factors which influence the risk? How can the risk be reduced? What is the role of antiretrovirals in reducing the risk?

4. Who Is at Risk? All HCPs who come in contact with blood or bloody fluids in hospitals or laboratories Nurses, laboratory workers, doctors, residents, paramedics, emergency doctors, medical students

5. Professionals with Frequent Blood Exposures Dentists Surgeons Emergency care providers Phlebotomists Nurses Labour and delivery personnel (Laboratory workers)

6. What Is The Risk? Occupational Percutaneous0.3% Mucous membrane0.09% Sexual transmission0.018% to 3% Mother to child25% Infected blood products95% Antiviral therapy 1998; 3 (Suppl 4): 45-47

7. Types of occupational injuries Needle sticks, scalpels, broken glass Contact with skin which is abraded, chapped, inflamed or an open wound Direct contact with concentrated HIV in a laboratory Isolated skin exposure Consultant Jan 1999; 230-6

8. Factors Influencing Risk Depth of injury Device visibly contaminated with blood Procedure involving a needle placed in artery or vein Type of needle (hollow bore or solid) Size of needle Source patient’s viral load Amount of blood Duration of exposure Immune status of HCP

9. Natural history of HIV infection

10. Body Fluids Which Can Transmit HIV Blood, bloody fluids Potentially infectious: semen, vaginal secretions, CSF, pleural, peritoneal, pericardial, amniotic fluids or tissue No risk: saliva, tears, sweat, non-bloody urine or faeces

11. Areas Of Contact Hands Body contact in cases of increased blood loss Face contact, common in orthopaedics and obstetrics Eye/mucous membrane contact

12. How Can Risks Be Reduced? Universal precautions Protocols for evaluation, counselling and treatment of occupational exposures Access to clinicians during all working hours Availability of antiretroviral agents for PEP on-site or easily Availability of trained personnel for counselling

13. How To Reduce Risk? Number of procedures Double gloves Gowns, facemasks, goggles. Care during procedures such as endoscopy, ENT surgery, others where splattering of blood is anticipated Use of impervious needle-disposal containers Transport of samples in sealed containers

14. Evaluation Of Exposure What is the source material? What is the kind of exposure? What is the status of source person/specimen? (HIV positive, end-stage disease, primary HIV infection, unknown) Is the HCP pregnant?

15. Treatment Of Exposure Immediate Measures Use of soap and water to wash any wound or skin Flush exposed mucous membrane with water Open wounds - irrigate with sterile saline or disinfectant solution Eyes should be irrigated with clean water, saline or sterile eye irrigants Report to the concerned authority Counselling Antiretroviral therapy

16. General Guidelines For PEP Therapy should be recommended after exposure Therapy should be initiated within 1-2 hours 2- and 3-drug regimens, based on level of risk Source patient’s HIV status unknown, decide on a case-to-case basis Follow up counselling and HIV testing using ELISA periodically for at least 6 months (baseline, 6 weeks, 12 weeks and 6 months) Potential benefits should be weighed against potential risks

17. Regimens For PEP Type Drugs BasicZidovudine 300 mg tid + Lamivudine 150 mg bid (28 days) (Duovir) OR Stavudine 30-40 mg bid + Lamivudine 150 mg bid (Lamivir-S) ExpandedAs above, plus (28 days)Indinavir (Indivan) 800 mg 8 hourly OR Efavirenz (Efavir) 600 mg od at bedtime OR Nelfinavir (Nelvir) 750 mg tid

18. POST EXPOSURE PROPHYLAXIS FOR HCP Source material: blood, bloody fluid, other potentially infectious fluid Type of exposure Intact SkinMucous membrane or non-intact skin Percutaneous exposure (no PEP needed) VolumeSeverity Small (ie few drops) More severe (eg large bore hollow needle) Large (ie major blood splash) Less severe (eg solid needle) Consider or recommend Basic regimen if source is HIV - positive; consider Basic regimen if source HIV status unknown Recommend Expanded regimen; consider Basic regimen if source HIV status unknown Recommend Basic or Expanded regimen if source is HIV-positive; consider Basic regimen if source HIV status unknown

19. Common Adverse Effects of PEP Nausea Malaise/fatigue Headache Vomiting Diarrhoea Myalgia/arthralgia Abdominal pain Rash

20. Counselling the exposed HCP Monitor for drug toxicity (minimally, CBC and LFT at baseline and at 2 wks) Evaluation of symptoms such as rash, fever, hyperglycemia, back or abdominal pain or pain on urination should not be delayed Potential drug interactions Failures can still occur Behavioural modifications